RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q1 2021
Top Holdings82 positions
ASCENDIS PHARMA A/S | 6.4M | $826.4M | 12.5% | $86.94 | +47.98% | 10 qtrssince 2018-Q4 | Increased 68 |
NOVAVAX INC | 3M | $544.3M | 8.2% | $102.60 | +76.71% | 4 qtrssince 2020-Q2 | Decreased 0 |
VOR BIOPHARMA INC | 11.1M | $479.3M | 7.2% | $781.20 | 0.00% | 1 qtr | New 97 |
ATEA PHARMACEUTICALS INC | 5.4M | $331.5M | 5.0% | $41.71 | +34.81% | 2 qtrssince 2020-Q4 | Unchanged 0 |
FORMA THERAPEUTICS HOLDINGS | 9M | $252.5M | 3.8% | — | — | 4 qtrssince 2020-Q2 | Unchanged 0 |
TG THERAPEUTICS INC | 4.6M | $223.5M | 3.4% | $8.58 | +427.48% | 10 qtrssince 2018-Q4 | Decreased 0 |
NKARTA INC | 5.6M | $184.4M | 2.8% | $30.36 | +3.19% | 3 qtrssince 2020-Q3 | Unchanged 0 |
| 3.6M | $182.3M | 2.7% | — | — | 6 qtrssince 2019-Q4 | Decreased 0 | |
MACROGENICS INC | 4.9M | $157.1M | 2.4% | $28.36 | +12.29% | 4 qtrssince 2020-Q2 | Increased 59 |
ITEOS THERAPEUTICS INC | 4.4M | $151M | 2.3% | — | — | 3 qtrssince 2020-Q3 | Unchanged 0 |
IMMUNOGEN INC | 18.4M | $149.2M | 2.2% | — | — | 3 qtrssince 2020-Q3 | Unchanged 0 |
TRAVERE THERAPEUTICS INC | 5.6M | $140.2M | 2.1% | $26.83 | -6.92% | 2 qtrssince 2020-Q4 | Increased 63 |
INSTIL BIO INC | 4.9M | $122.2M | 1.8% | $484.80 | 0.00% | 1 qtr | New 69 |
PHATHOM PHARMACEUTICALS INC | 3.1M | $117M | 1.8% | $32.43 | +11.97% | 6 qtrssince 2019-Q4 | Decreased 0 |
89BIO INC | 4.7M | $112.2M | 1.7% | — | — | 6 qtrssince 2019-Q4 | Unchanged 0 |
KINNATE BIOPHARMA INC | 3.6M | $112M | 1.7% | — | — | 2 qtrssince 2020-Q4 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 4.9M | $103.6M | 1.6% | $23.56 | -9.70% | 10 qtrssince 2018-Q4 | Increased 55 |
ZOGENIX INC | 5.3M | $103.1M | 1.6% | — | — | 10 qtrssince 2018-Q4 | Decreased 0 |
AXSOME THERAPEUTICS INC. | 1.7M | $93.7M | 1.4% | $50.95 | +9.73% | 9 qtrssince 2019-Q1 | Unchanged 0 |
ROCKET PHARMACEUTICALS INC | 2.1M | $93.5M | 1.4% | $54.84 | -19.09% | 2 qtrssince 2020-Q4 | Decreased 0 |
RA CAPITAL MANAGEMENT, L.P. manages $6.6B across 82 positions as of Q1 2021. Top holdings: ASND (12.5%), NVAX (8.2%), VOR (7.2%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2/5.0.
Active quarter - 19 new positions, 19 exits, 9 increased. Top move: VOR (NEW, conviction 97). Portfolio: $6.6B across 82 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR